Nuveen
IMRX icon

Nuveen’s Immuneering IMRX Stock Holding History

Nuveen’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
+438,362
New +$2.22M ﹤0.01% 2536
2024
Q2 		– Sell
-44,049
Closed -$127K – 3375
2024
Q1 		$127K Hold
44,049
– – ﹤0.01% 3234
2023
Q4 		$324K Buy
44,049
+3,504
+9% +$23.3K ﹤0.01% 3131
2023
Q3 		$311K Hold
40,545
– – ﹤0.01% 2955
2023
Q2 		$411K Buy
+40,545
New +$390K ﹤0.01% 2959
2022
Q2 		– Sell
-27,047
Closed -$196K – 3367
2022
Q1 		$196K Buy
27,047
+15,287
+130% +$147K ﹤0.01% 3197
2021
Q4 		$247K Hold
11,760
– – ﹤0.01% 3205
2021
Q3 		$312K Buy
+11,760
New +$316K ﹤0.01% 3245

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Nuveen's IMRX Position: Q2 2026 in Review

Nuveen opened a new position in Immuneering (IMRX) in Q2 2026: 438,362 shares worth $2.19M. The stake represents ﹤0.01% of the portfolio and ranks #2536 among its holdings. This is a return to the name: Nuveen previously reported a position in IMRX as recently as Q1 2024.

Nuveen first reported a position in IMRX in Q3 2021 and has held it in 8 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Nuveen held 438,362 shares of Immuneering worth $2.19M as of Q2 2026.
  • Immuneering was a new Nuveen position in Q2 2026.
  • Immuneering made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2536 holding.
  • Nuveen first reported a position in Immuneering in Q3 2021 and has held it in 8 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.